Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Naples – page 93

1 221 clinical trials in Naples, Italy across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Naples at a glance
1 221
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

1 221 trials in Naples

Open in trial search

Uveal melanoma

Not recruiting

Study of Darovasertib for Patients with Localized Uveal Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Darovasertib
  • Sponsor:Ideaya Biosciences Inc.

Bladder cancer+2

Not recruiting

Study of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Repotrectinib and Crizotinib for Patients with Advanced or Metastatic ROS1-positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of DCC-3116 with Sotorasib, Binimetinib, and Trametinib for Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:DCC-3116
  • Sponsor:Deciphera Pharmaceuticals Inc.

Follicular lymphoma+1

Not recruiting

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Malignant melanoma

Not recruiting

Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Breast cancer+2

Not recruiting

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Safety and Effectiveness of Pembrolizumab, Lenvatinib, and Quavonlimab for Patients with Advanced Melanoma with Brain Metastases

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Study on Frexalimab for Treating Active Systemic Lupus Erythematosus in Patients

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Lung disorder

Not recruiting

Study on Baricitinib for Hospitalized Patients with Severe or Critical COVID-19

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Oslo University Hospital HF

Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:F. Hoffmann-La Roche AG

Lung disorder

Not recruiting

Study on the Effectiveness and Safety of Bemcentinib for Hospitalized Patients with Moderate COVID-19

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bemcentinib
  • Sponsor:Oslo University Hospital HF

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Naples

What the registry says about research in the country

01 Respiratory Diseases

Research focusing on pulmonary conditions including innovative treatments for idiopathic pulmonary fibrosis and COPD. Studies evaluate new medications like tezepelumab and investigate respiratory syncytial virus vaccines for older adults.

  • Idiopathic Pulmonary Fibrosis
  • COPD Management
  • RSV Prevention

Clinical trials aim to improve lung function and reduce disease progression in patients with chronic respiratory conditions.

02 Oncology Research

Comprehensive studies targeting various cancer types, with emphasis on targeted therapies and immunological approaches. Investigations include treatments for colorectal, gastric, and lung cancers.

  • Breast Cancer Prevention
  • Gastrointestinal Cancers
  • Advanced Solid Tumors

Novel therapeutic combinations and precision medicine approaches are being evaluated for improved patient outcomes.

03 Chronic Diseases

Studies addressing kidney disease, cardiovascular conditions, and neurological disorders. Innovative treatments for Parkinson's disease and end-stage kidney disease are under investigation.

  • Kidney Disease Management
  • Heart Failure Prevention
  • Neurological Disorders

Research focuses on developing safer and more effective treatments for chronic conditions affecting quality of life.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.